Page 15 - Immunology

Messenger RNA can be used for protein expression into the cells. The delivery of mRNA is the delivery of a new function that can activate a biological process. In the particular case of the CAS9 mRNA,

RNA-based CRISPR-CAS9 gene editing is a vector-free approach that is required for therapeutic perspectives. However, from a practical point of view, what appears as a major challenge to engineer

Cell-based assays, screening for pathway activation or inhibition are classically done with promoter reporter clones expressing Firefly luciferase. Brighter, more stable, more sensitive, more convenient

RayBiotech , the antibody array specialist, have just released a new, very broad antibody microarray, the L2000 series, for the profiling of 2000 protein targets including

If your research interest is focused on the identification of cell signalling pathways and protein phosphorylation profiles, the comprehensive Phospho Explorer Array may be of great help

Antibody generation raises a number of questions... what is the difference between their classes, forms and types? And how do recombinant monoclonal antibodies (rAbs) overcome the drawbacks

As they say, a good picture is worth a thousand words. That's to say that I'll have to keep the introduction short in this post (!) to let you know about this interesting map from Boster Bio

Personalized treatment for cancer reached a new milestone with the FDA approval of CAR T-cells for treatment of leukemia and lymphoma.  There is now rapid growth in research on the therapeutic uses of

A new Hemoglobin (Hgb) High Sensitivity kit has just been released to allow for the detection of Hgb in low amount of samples. Researchers working on inflammation, kidney injury or oxidative

When doing WBs, IFs or IHCs, we normally pay a lot of attention to the primary antibody that should be chosen. We look at the datasheet, we check that the primary antibody has been validated for the species

Whether your protein is simple to produce, or complex and requires more development, in any case, outsourcing your protein expression, purification and production is a very viable option

One of the challenges in R&D is to find robust technologies to develop diagnostic tests. Notably, it could be within a context of asymptomatic infections for which reliable detection of positive specimens